ONT-093 (Ontogen).
Ontogen is developing ONT-093 (formerly OC-144-093), a P-glycoprotein pump inhibitor, for the potential reversal of multidrug resistance in patients undergoing cancer chemotherapy. The compound is also being evaluated for its potential enhancement of the oral bioavailability of drugs that are P-glycoprotein substrates requiring either high dosage forms or intravenous administration, and for the potential improvement of central nervous system penetration of P-glycoprotein substrate drugs.
Mistry
Prakash
P
Xenova Ltd, 957 Buckingham Avenue, Slough, Berkshire, SL1 4NL, UK. prakash_mistry@xenova.co.uk
Folkes
Adrian
A
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D018432:Drug Resistance, Multiple / Q000502:physiology; D006801:Humans; D007093:Imidazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
D007093:Imidazoles; C410029:OC 144-093